Cooperative Agreement U01CA233085

GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $2,098,194 project grant to Tilt Biotherapeutics OY to research novel cancer immunotherapies. The three-year project, titled "UNLEASHING THE FULL POTENTIAL OF CHECKPOINT INHIBITOR ANTIBODIES WITH T-CELL-STIMULATING ONCOLYTIC ADENOVIRUSES FOR TREATMENT OF OVARIAN CANCER", aims to develop a combination therapy using checkpoint inhibitor antibodies and oncolytic adenoviruses to...

This $2,014,500 project grant from the Defense Health Agency was awarded to Health Research, Inc. - Roswell Park Division to conduct a randomized Phase 2 clinical trial evaluating pembrolizumab combined with bevacizumab, with or without the anti-CD40 agonist CDX-1140, in patients with recurrent ovarian cancer. The grant was provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for...

Summary The National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) awarded a $683,970 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) beginning April 1, 2026, with completion targeted for March 31, 2031. This award supports research aimed at modifying the pancreatic cancer tumor microenvironment through the αvβ5 integrin pathway. The research focuses on developing and evaluating the IRGD tumor-penetrating peptide as a...

This $816,676 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a study by the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to conduct a multiomic evaluation of ovarian cancer responses to heated intraperitoneal chemotherapy (HIPEC). The 3-year study, with a period of performance from September 30, 2024 to August 31, 2027, aims to advance understanding of how HIPEC...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $713,312 Project Grant to Health Research, Inc. (operating as Health Research At Roswell Park) on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). This five-year research initiative, concluding May 31, 2031, focuses on elucidating the impacts of body composition and physical activity on anti-tumor immunity and cancer control in high-grade serous ovarian carcinoma (HGSOC). The...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...

This federal Project Grant award of $270,981 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a five-year research program to investigate resistance mechanisms to anti-PD-1/L1 immunotherapy in hepatobiliary cancers. The key objectives are to: Conduct a Phase 2 trial evaluating an anti-TIGIT plus anti-PD-1 antibody combination in hepatobiliary cancers refractory to PD-1 blockade. Characterize immune and molecular features of anti-PD-1/L1 therapy-resistant...

Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded April 1, 2026, with completion targeted for March 31, 2028. The grant supports research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugate cancer therapy, specifically examining sacituzumab govitecan (SG), which is approved for...

This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...